证券代码：002907 证券简称：华森制药 公告编号：2025-054 重庆华森制药股份有限公司 关于公司产品完成境内生产药品备案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日从国家药品监督管 理局（以下简称"国家药监局"）网站查询获知公司产品苍耳子鼻炎胶囊完成境 内生产药品备案（延长药品有效期申请），并于国家药监局网站公示备案信息。 现将相关情况公告如下： 一、药品基本信息 （一）延长药品有效期申请 1.苍耳子鼻炎胶囊 药品通用名称 ： 苍耳子鼻炎胶囊 备案号 ： 渝备 2025021509 药品批准文号 / 原料药登记号 ：国药准字 Z20033142 上 市 许 可 持 有 人 ：重庆华森制药股份有限公司 上市许可持有人地址 ： 重庆市荣昌区工业园区 生产企业名称 ：重庆华森制药股份有限公司 生产企业地址 ： 重庆市荣昌区昌州街道板桥路 143 号 四、风险提示 备 案 内 容 ： 延长本品有效期由 18 个月变更为 24 个月 备 案 机 关 ：重庆市药品监督管理局 备 案 日 期 ：2025 ...

21世纪经济报道记者肖夏 重庆荣昌报道 "这两天生意确实还可以，还好你打电话预约了，你看全都坐满了。" 忙着颠勺的陈续勇笑着看了一眼21世纪经济报道记者，赶紧回头看锅里，生怕火候过了。 陈续勇夫妇是重庆市荣昌区本地人。六年前，夫妇俩在荣昌的迎宾大道和民安街路口开出这家家常菜 馆"一闻知味"。店面不大，路人稍不留神就会错过。 6月末的一天，被网友称为"荣昌老高"的重庆市荣昌区委书记高洪波迈进了陈续勇的馆子，自掏腰包扫 码预付了2000元，请了两桌企业家吃饭。 这顿饭最终实际消费1100元。当天和他一同就餐的20余人中，有到访荣昌的营销专家华红兵，全国劳 模、荣昌兴旺种猪场场长郭平，重庆市人大代表、华森制药（002907）董事长游洪涛，全国人大代表、 荣昌养猪龙头企业琪金食品董事长林其鑫，以及"桃二妹"等几位90后创业者。 用高书记的话说，这顿饭覆盖了荣昌一、二、三产业的重要参与者。 新闻并未提及具体店名，但荣昌人都知道，高书记又出来支持本地商家生意了。在鼓励扩大内需、提振 消费信心的当下，"带头消费、带领消费"的高书记又一次成为全网焦点。 不只是陈续勇家的餐馆。21世纪经济报道记者近日在荣昌走访发现，不少高书记 ...

Group 1 - Betta Pharmaceuticals announced the approval of its CDK4/6 inhibitor, Tarecili, for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer in adults who have progressed after endocrine therapy [1] - Tarecili is a new molecular entity developed independently by Betta Pharmaceuticals, targeting CDK4/6, and is the eighth CDK4/6 inhibitor approved in China [1] - The competitive landscape for CDK4/6 inhibitors is intense, and Betta Pharmaceuticals needs to establish a differentiated competitive advantage for Tarecili to succeed commercially [1] Group 2 - Guangji Pharmaceutical received a notice of administrative penalty from the Hubei Regulatory Bureau for suspected violations of information disclosure, with a proposed fine of 1.5 million yuan and warnings issued to the former chairman and CFO [2] - The penalties reflect significant internal control deficiencies within Guangji Pharmaceutical, which may negatively impact the company's reputation and investor confidence [2] Group 3 - Huason Pharmaceutical received approval for clinical trials of its CX001 sustained-release tablets for the treatment of postherpetic neuralgia, marking a milestone for the company's innovative drug development platform [3] - CX001 is still in the early stages of development, and investors should closely monitor its clinical progress before it can generate revenue [3] Group 4 - Sunshine Nuohua signed a technical development cooperation contract with Shanghai Lekuang Huilin Pharmaceutical Technology, with a total contract value of 200 million yuan for the STC007 project, which is currently in Phase III clinical trials [4] - The collaboration aims to leverage both parties' strengths to accelerate the commercialization of STC007, potentially positively impacting Sunshine Nuohua's current and future financial performance [4] Group 5 - Ruikang Pharmaceutical announced that its director, secretary of the board, and vice president Li Zhe has been placed under detention by the Jinan Municipal Supervisory Committee, while other executives continue to perform their duties normally [5] - Despite the company's assertion of a sound governance structure, the detention of a senior executive may raise concerns in the capital market regarding the company's future operational development [5]

Group 1 - Guizhou Moutai has repurchased a total of 3.3821 million shares as of June 30, 2025, accounting for 0.2692% of the total share capital, with a total expenditure of 5.202 billion yuan [2] - Luxshare Precision is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global financing capabilities and governance transparency [2] - Huazhong Xinchuang has received a project notification from a leading domestic eVTOL manufacturer for the development and supply of an intelligent cockpit multimedia display system [3] Group 2 - Meinohua expects a net profit of 46 million to 52 million yuan for the first half of 2025, representing a year-on-year increase of 142.84% to 174.52% [4] - Jiangnan Water has received a report from shareholder Lianan Life Insurance indicating an increase in shareholding by 46.99 million shares, representing 5.03% of the total share capital [5] - Huasen Pharmaceutical has received approval for clinical trials of its CX001 sustained-release tablets, marking a milestone for its innovative drug development platform [6] Group 3 - Zongshen Power anticipates a net profit growth of 70% to 100% for the first half of the year [7] - Yutong Bus reported a sales volume of 5,919 units in June, a year-on-year increase of 24.79% [7] - Guangzhou Port expects a 7.0% year-on-year increase in container throughput for June 2025 [7] Group 4 - Data Port's shareholders plan to reduce their holdings by up to 1.74% and 0.26% of the company's shares [9] - Humanwell Healthcare's shareholder plans to increase its stake by 1% to 2% [9] - Nengte Technology plans to repurchase shares worth between 300 million to 500 million yuan [10]

CX001 缓释片为公司自研产品，将速释制剂改良为缓释制剂（胃滞留缓释片）， 该缓释制剂可降低给药频率、增加患者顺应性、提高睡眠质量。本次申请开展 临床试验的适应症为用于治疗带状疱疹后神经痛。 三、对公司的影响 CX001 缓释片是公司首个获批临床的改良型创新药项目，对公司改良型创 新药研发平台的发展具有里程碑意义。由于药物研发的特殊性，药物从临床试 证券代码：002907 证券简称：华森制药 公告编号：2025-053 重庆华森制药股份有限公司 关于公司获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的《药物临床试验批准通知书》。 现将相关情况公告如下： 一、药物临床试验批准通知书的主要内容 | 药 | 物 | 名 | 称：CX001 缓释片 | | --- | --- | --- | --- | | 剂 | | | 型：缓释片剂 | | 申 | 请 | 事 | 项：临床试验申请 | | 注 | 册 | 分 | 类：化 ...

华森制药（002907）公告，公司近日收到国家药监局核准签发的《药物临床试验批准通知书》，主要内 容为：药物名称CX001缓释片，剂型为缓释片剂，申请事项为临床试验申请，注册分类为化学药品2.2 类，申请人为重庆华森制药股份有限公司。根据《中华人民共和国药品管理法》及有关规定，经审查， 同意本品开展"用于治疗带状疱疹后神经痛"适应症的临床试验。CX001缓释片为公司自研产品，将速释 制剂改良为缓释制剂(胃滞留缓释片)，该缓释制剂可降低给药频率、增加患者顺应性、提高睡眠质量。 ...

Core Viewpoint - Chengdu Dijiang, the controlling shareholder of Huason Pharmaceutical, has reduced its shareholding due to funding needs, but this change will not affect the company's control or ongoing operations [1][3]. Shareholding Changes - Before the recent changes, Chengdu Dijiang and its concerted parties held a total of 287,123,875 shares, accounting for 68.76% of the total share capital. After the reduction, they now hold 283,965,675 shares, which is 68.00% of the total [1][2]. - The reduction involved selling 948,400 shares through centralized bidding and 2,209,800 shares through block trading, totaling 3,158,200 shares sold [1][2]. Financial Performance - In 2024, Huason Pharmaceutical reported a revenue of 775 million yuan, a year-on-year increase of 12.04%. The net profit attributable to shareholders was approximately 76.73 million yuan, up 134.66% compared to the previous year [4][5]. - The net cash flow from operating activities was 161.77 million yuan, showing a decline of 26.25% year-on-year [4][5]. - Basic earnings per share increased to 0.1837 yuan, reflecting a growth of 134.61% [4][5]. Shareholding Structure - The shareholding structure indicates that Chengdu Dijiang holds 41.24% of the shares as unrestricted, while 17.34% are under restricted conditions. The total number of shares held by Chengdu Dijiang and its concerted parties has decreased from 290,472,175 shares (69.56%) to 283,965,675 shares (68.00%) [2][3].

根据市场公开信息及6月26日披露的机构调研信息，知名私募谦璞投资近期对1家上市公司进行了调研， 相关名单如下： 谦璞投资，由一批熟悉中国、美国资本市场和金融学术研究的专业人士创立，是一家结合中国金融市场 实际操作和顶尖金融学术研究的科技密集型资产管理公司。公司致力于运用先进的金融科学技术以及对 中国金融市场和特定行业的深入研究，为客户创造稳健、持续、风险可控和高质量的投资回报。 1）华森制药 （上海谦璞投资管理有限公司参与公司分析师会议） 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 机构简介： 调研纪要：华森制药介绍了重点中成药产品的再开发规划，2024年八味芪龙颗粒和六味安神胶囊获批国 家首家中药二级保护品种。公司销售终端以公立医院为主，院内市场约占七成，同时积极布局其他销售 渠道。华森英诺拥有7个1.1类创新药在研项目，其中注射用盐酸ORIC-1940正在进行临床Ia/Ib期研究。 公司TY005项目获得特医食品注册证书，特医食品生产线将逐步释放产能。研发投入下降主要因资本化 项目金额减少，开发阶段项目支出较往年减少。公司重点 ...

Report Summary 1. Report Industry Investment Rating No information provided in the given content. 2. Core Viewpoints of the Report - The company's key Chinese patent medicines have strong market potential and are in the growth stage. The company is actively promoting the renewal of Chinese patent medicine protection, academic system construction, and market access work, and the Chinese patent medicine sector remains the ballast for the company's performance [22]. - Through the integration with Aorui Pharmaceutical, the company has enhanced its R & D capabilities in small - molecule innovative drugs, with 7 self - initiated Class 1.1 innovative drug R & D projects in progress, covering tumor and autoimmune disease fields [24]. - In the context of centralized procurement, the company adheres to the strategy of diversified development in advantageous fields, expands product pipelines and market channels, and actively seeks new performance growth points [27]. 3. Summary by Relevant Catalogs 3.1. Research Basic Situation - The research object is Huasen Pharmaceutical, belonging to the Chinese medicine industry. The reception time was June 26, 2025, and the listed company's reception staff included the securities affairs representative Zhou Zhiru, and securities affairs specialists Xu Jun and Long Jie [17]. 3.2. Detailed Research Institutions - The reception object is Shanghai Qianpu, a type of investment company. The relevant institutional personnel include General Manager and Fund Manager Chen Shi, and Researcher Wu Shunyu [20]. 3.3. Research Institution Proportion No information provided in the given content. 3.4. Main Content Data - **Chinese Patent Medicine Business** - The company's five key Chinese patent medicines are in the growth stage. In 2024, two products were approved as the first national second - level protected Chinese patent medicine varieties, delaying the protection period by 7 years. In Q1 2025, the revenue of the five key Chinese patent medicines increased by 24.49% year - on - year, and from the beginning of the year to the reporting date, it increased by 31.44%. Among them, the revenue of Ganju Bingmei Tablets increased by 38.84% during the reporting period and 54.36% from the beginning of the year to the reporting date [22]. - The company's sales terminal is still mainly public hospitals, with about 70% in the in - hospital market. It drives the coordinated development of multiple channels and plans to increase the proportion of the out - of - hospital market [23]. - The company attaches great importance to building the academic system of key varieties, and the five key Chinese patent medicines have received 32 recommendations from authoritative materials, indicating high recognition [23]. - **Innovative Drug R & D** - In May 2025, Huasen Yinuo increased its stake in and controlled Aorui Pharmaceutical, and now has 7 self - initiated Class 1.1 innovative drug R & D projects, with the most advanced project, Injectable Hydrochloride ORIC - 1940, in the clinical Ia/Ib phase [24]. - The company plans to submit IND applications for two other projects before the end of this year and in the first quarter of next year [25]. - **Special Medical Food** - The company has 4 self - developed special medical food projects. The TY005 project has obtained relevant certificates, and the production line will gradually release production capacity. The company is exploring digital marketing and multi - channel promotion [25]. - **Overseas Market** - The company's fifth - phase production base passed the US FDA's cGMP on - site inspection in May 2023. Four key Chinese patent medicines obtained registration approvals in Singapore from 2024 to 2025, marking a key milestone for product exports [27]. - **Response to Centralized Procurement** - The company's strategy is to explore diversified development in advantageous fields. In the R & D end, it focuses on product listing and has built a "333" pipeline pattern. In market expansion, it develops multiple channels. In product layout, it actively arranges special medical food and other varieties [27]. - **ORIC - 1940 Research Progress** - It is expected that a certain amount of Ib - phase data will be generated next year, and the specific data reading date depends on the patient enrollment speed. ORIC - 1940 shows good safety in pre - clinical studies and is expected to be a new treatment option for HLH [28]. - **Advantages of ORIC - 1940 in HLH Treatment** - ORIC - 1940 can inhibit necroptosis and pan - apoptosis, reduce DAMPs levels, which is a differentiated molecular mechanism compared with other therapies and provides a new treatment option for HLH [29].

证券代码：002907 证券简称：华森制药 公告编号：2025-052 重庆华森制药股份有限公司 关于控股股东及其一致行动人持股变动触及 1%整数 倍的公告 公司控股股东成都地方建筑机械化工程有限公司及其一致行动人游洪涛先生、 王瑛女士、上海添橙投资管理有限公司－添橙添利一号私募证券投资基金保证向本 公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 本次减持与此前已披露的减持计划一致，减持数量在已披露的减持计划范围 内，不存在违反已披露的减持计划及相关承诺的情形。 本次变动是否存在 违反《证券法》《上 市公司收购管理办 法》等法律、行政法 规、部门规章、规范 性文件和本所业务 规则等规定的情况 是□ 否☑ 如是，请说明违规的具体情况、整改计划和处理措施。 5．被限制表决权的股份情况 按照《证券法》第六 十三条的规定，是否 存在不得行使表决 权的股份 是□ 否☑ 如是，请说明对应股份数量及占现有上市公司股本的比 例。 6．备查文件 1．中国证券登记结算有限责任公司持股变动明细 ☑ 2．相关书面承诺文件 □ 3．律师的书面 ...